Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer

被引:2
|
作者
Liu, Jiaqi [1 ]
Zeng, Xiaoxiao [1 ,2 ]
Zhou, Xiaojuan [1 ]
Xu, Yong [1 ]
Ding, Zhenyu [3 ]
Hu, Yang [4 ]
Yuan, Yong [4 ]
Chen, Longqi [4 ]
Wang, Jin [1 ]
Lu, You [1 ]
Liu, Yongmei [1 ,5 ]
机构
[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Thorac Oncol, Chengdu 610041, Sichuan, Peoples R China
[2] Peoples Hosp Jianyang City, Dept Oncol, Jianyang 641400, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu 610041, Sichuan, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Thorac Surg, Chengdu 610041, Sichuan, Peoples R China
[5] Sichuan Univ, West China Hosp, Canc Ctr, Dept Thorac Oncol, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China
关键词
esophageal cancer; neoadjuvant chemoradiotherapy; optimal time interval; pathological response; survival; CARCINOMA;
D O I
10.3892/ol.2023.13741
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neoadjuvant chemoradiotherapy (nCRT) has been shown to reduce tumor burden and achieve tumor regression in patients with esophageal cancer (ESC). However, the most beneficial time interval between the administration of nCRT and surgery remains unclear. Therefore, the aim of the present study was to explore the association of the duration of time between nCRT and surgery with the prognosis of patients with ESC. Patients with ESC who received nCRT following surgical resection (n=161) were reviewed and divided into the prolonged time interval group (time interval >= 66 days) and the short time interval group (time interval <66 days), according to the median value. Subsequent analysis revealed that the prolonged time interval group achieved a higher pathological complete response (pCR) rate compared with the short time interval group (49.4 vs. 26.3%; P=0.003). Furthermore, multivariate logistic regression analysis showed that it was possible to independently estimate a higher pCR rate based on a prolonged time interval (odds ratio, 2.131; P=0.042). However, no association between a prolonged time interval and disease-free survival (DFS) was detected using Kaplan-Meier curves (P=0.252) or multivariate Cox regression (P=0.607) analyses. Similarly, no association was identified between a prolonged time interval and overall survival (OS; P=0.946) based on Kaplan-Meier curve analysis, and subsequent multivariate Cox regression analyses showed that the time interval also failed to independently estimate OS (P=0.581). Moreover, female sex (P=0.001) and a radiation dose >= 40 Gy (P=0.039) served as independent factors associated with a higher pCR rate, and the pCR rate was an independent predictor of favorable DFS (P=0.002) and OS (P=0.015) rates. In conclusion, the present study revealed that a prolonged time interval from nCRT to surgery was associated with a higher pCR rate, but it failed to estimate the survival profile of patients with ESC.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Linkage of time interval from neoadjuvant chemoradiotherapy to surgery with pathological response and survival profile in resectable esophageal cancer patients.
    Liu, Jiaqi
    Zeng, Xiaoxiao
    Zhou, Xiaojuan
    Xu, Yong
    Ding, Zhenyu
    Hu, Yang
    Yuan, Yong
    Chen, Longqi
    Wang, Jin
    Lu, You
    Liu, Yongmei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16071 - E16071
  • [2] Neoadjuvant chemoradiotherapy with consecutive surgery in patients with resectable esophageal cancer.
    van de Schoot, L
    van der Sangen, M
    Creemers, GJ
    van Driel, OJR
    Rutten, HJT
    Nieuwenhuijzen, GAP
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2005, 17 (01) : A41 - A41
  • [3] Evaluation of survival and recurrence patterns in esophageal cancer patients with pathological response to neoadjuvant chemoradiotherapy
    Kermani, Ali Taghizadeh
    Bagheri, Reza
    Taheri, Hessam
    Aliakbarian, Mohsen
    Soltani, Ehsan
    Joudi, Mona
    [J]. KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 16 (04) : 186 - 193
  • [4] Does neoadjuvant chemoradiotherapy increase survival in patients with resectable oesophageal cancer?
    Buderi, Silviu I.
    Shackcloth, Michael
    Page, Richard D.
    [J]. INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2017, 24 (01) : 115 - 120
  • [5] Longer Interval between Neoadjuvant Chemoradiotherapy and Surgery for Rectal Cancer. Does it Affect Recurrence Rates?
    Rabie, M.
    Blake, L.
    Evans, J.
    [J]. BRITISH JOURNAL OF SURGERY, 2018, 105 : 150 - 150
  • [6] Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer
    Daniel W. Kim
    Grace Lee
    Theodore S. Hong
    Guichao Li
    Nora K. Horick
    Eric Roeland
    Florence K. Keane
    Christine Eyler
    Lorraine C. Drapek
    David P. Ryan
    Jill N. Allen
    David Berger
    Aparna R. Parikh
    John T. Mullen
    Sam J. Klempner
    Jeffrey W. Clark
    Jennifer Y. Wo
    [J]. Annals of Surgical Oncology, 2022, 29 : 242 - 252
  • [7] Longer Time Interval Between ERCP and Surgery Associated with Improved Survival in Pancreatic Cancer Patients
    Rustgi, Sheila D.
    Amin, Sunil
    Kim, Michelle
    Nagula, Satish
    DiMaio, Christopher J.
    Lucas, Aimee L.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S11 - S11
  • [8] Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer
    Kim, Daniel W.
    Lee, Grace
    Hong, Theodore S.
    Li, Guichao
    Horick, Nora K.
    Roeland, Eric
    Keane, Florence K.
    Eyler, Christine
    Drapek, Lorraine C.
    Ryan, David P.
    Allen, Jill N.
    Berger, David
    Parikh, Aparna R.
    Mullen, John T.
    Klempner, Sam J.
    Clark, Jeffrey W.
    Wo, Jennifer Y.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (01) : 242 - 252
  • [9] Interval between neoadjuvant chemoradiotherapy and Surgery for Patients with locally advanced Esophageal Cancer -When to operate?
    Schroeder, W.
    Bruns, C. J.
    [J]. CHIRURGIE, 2024, 95 (01): : 80 - 81
  • [10] Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival
    Berger, AC
    Farma, J
    Scott, WJ
    Freedman, G
    Weiner, L
    Cheng, JD
    Wang, H
    Goldberg, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) : 4330 - 4337